Tern’s Bruce Leith appointed Executive Chairman of Purple Transform

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IOT) technology businesses, has announced that Bruce Leith, the Company’s Business Development Director, a non-board position, has been appointed as Executive Chairman of Purple Transform Limited.  Tern will be paid the fees for Bruce Leith’s services.

Purple Transform is a company that Sure Valley Ventures Enterprise Capital LP (SVV2) is invested in.  As announced on 2 March 2022, Tern has previously committed to invest up to £5 million in SVV2 over the 10-year life of SVV2. Tern has a 6.1% holding in SVV2.

Commenting, Ian Richie, Chairman of Tern, said: “As I have previously stated, Tern’s focus is on realisations, but we will take appropriate opportunities to utilise the skills and experience of the Tern team’s hands on approach to generate income for Tern, without detracting from our primary purpose.  Bruce’s appointment to assist Purple Transform will not only provide a modest income stream for Tern, but it is intended to help drive value creation in the Purple Transform business that Tern will benefit from through its holding in SVV2.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pharma faces a strategic turning point in AI adoption

AI in pharma is moving from operational support to strategic driver as companies prioritise messaging that delivers measurable prescriber impact.

Tern Plc updates position in Talking Medicines with new convertible loan notes

Tern Plc has received about £230,000 in new unsecured convertible loan notes from Talking Medicines after cancelling around £180,000 of short term loans provided over 2024 and 2025.

The real problem holding back connected vehicle programmes

Vehicle identity is fast becoming a core infrastructure challenge, and a new bottleneck for OEMs aiming to scale software-defined platforms.

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Search

Search